Inhaler delivery method coupled with SEDDS technology provides 2 unique benefits. As already used for asthma, a medical inhaler provides for much faster delivery directly into the blood stream by way of the lungs and SEDDS technology provides for a higher absorption rate into the blood stream as well. The carefully worded press release did not indicate immediate revenue but was categorized as immediate revenue 'opportunity'. Medipharm Labs did "license" this technology on an exclusive basis....they bought 'the rights' via a royalty agreement.
Technology 'cobbling', bringing together different technologies for a targeted application, examples being the SEDDS technology and the pharmaceutical medical inhaler, no different than those used for asthma. An example of those being cobbled together for a target could easily be applied in many applications, including the launch this year of generic Epidiolex. CBD cannot be patented because it is naturally occuring but SEDDS and Remidose inhaler technology can be and thus providing a very unique delivery method comapred to JAZZ witih CBD suspended in seasame oil and take orally as a liquid.
The Remidose licensing deal did not happen over night and as the owner of Remidose, why would that person even consider doing such a deal based on "100% performance based payment" unless volume and performance esttimates were shared with Remidose as related to generic Epidiolex and potentially other applications as well.
ps: Has anyone looked a little deeper to see if other than securing more avian bird flu vaccines and test kits if the CDC has also looked at inhalers as well? The effectiveness of a CBD compound via an inhaler was already proven during the later stages of COVID and tested as well against lung inflammation brought on by avian bird flu.
- MediPharm has licenced global manufacturing, distribution, and sales rights of the novel advanced medical cannabis technology from Remidose Aerosols.
- Products include metered dose inhalers and aerosol sublingual sprays.
- MediPharm will assume existing Remidose sales allowing for immediate revenue opportunity.
- Transaction is non-dilutive, with 100% performance-based payment through a royalty model.